Lantheus Holdings, Inc. (NASDAQ:LNTH) Shares Acquired by Stifel Financial Corp

Stifel Financial Corp raised its position in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 14.3% during the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 38,497 shares of the medical equipment provider's stock after acquiring an additional 4,816 shares during the period. Stifel Financial Corp owned about 0.06% of Lantheus worth $3,444,000 as of its most recent filing with the SEC.

A number of other hedge funds have also added to or reduced their stakes in the business. Reinhart Partners LLC. lifted its position in Lantheus by 9.9% during the fourth quarter. Reinhart Partners LLC. now owns 1,366,873 shares of the medical equipment provider's stock worth $122,280,000 after acquiring an additional 123,282 shares during the last quarter. Dimensional Fund Advisors LP grew its stake in shares of Lantheus by 2.3% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,347,082 shares of the medical equipment provider's stock worth $120,510,000 after buying an additional 30,891 shares during the last quarter. Swedbank AB raised its position in Lantheus by 53.3% in the fourth quarter. Swedbank AB now owns 1,107,243 shares of the medical equipment provider's stock valued at $99,054,000 after purchasing an additional 385,000 shares during the last quarter. Portolan Capital Management LLC raised its holdings in Lantheus by 21.1% in the 4th quarter. Portolan Capital Management LLC now owns 812,630 shares of the medical equipment provider's stock valued at $72,698,000 after buying an additional 141,749 shares during the last quarter. Finally, Raymond James Financial Inc. acquired a new position in shares of Lantheus in the fourth quarter worth approximately $36,183,000. Institutional investors own 99.06% of the company's stock.

Insider Buying and Selling

In other news, CFO Robert J. Jr. Marshall sold 10,000 shares of the firm's stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $100.52, for a total value of $1,005,200.00. Following the transaction, the chief financial officer now directly owns 113,860 shares of the company's stock, valued at approximately $11,445,207.20. This trade represents a 8.07 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Mary Anne Heino sold 53,107 shares of the stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $94.35, for a total transaction of $5,010,645.45. Following the completion of the sale, the director now owns 440,399 shares of the company's stock, valued at approximately $41,551,645.65. The trade was a 10.76 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 63,109 shares of company stock worth $6,016,046 in the last 90 days. 2.00% of the stock is owned by corporate insiders.

Lantheus Trading Down 0.6 %

Shares of NASDAQ LNTH traded down $0.50 during midday trading on Thursday, hitting $79.99. The company's stock had a trading volume of 933,471 shares, compared to its average volume of 956,629. Lantheus Holdings, Inc. has a 12-month low of $74.28 and a 12-month high of $126.89. The firm has a market cap of $5.48 billion, a P/E ratio of 13.31 and a beta of 0.23. The business's 50 day moving average is $100.19 and its two-hundred day moving average is $94.79.

Lantheus (NASDAQ:LNTH - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The medical equipment provider reported $1.53 earnings per share for the quarter, missing the consensus estimate of $1.64 by ($0.11). The business had revenue of $372.76 million during the quarter, compared to analysts' expectations of $377.37 million. Lantheus had a return on equity of 44.29% and a net margin of 28.57%. Lantheus's revenue for the quarter was up .8% on a year-over-year basis. During the same period in the previous year, the company posted $1.69 EPS. On average, analysts predict that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on LNTH shares. JMP Securities reiterated a "market outperform" rating and issued a $112.00 target price on shares of Lantheus in a report on Tuesday, January 14th. Truist Financial reduced their target price on shares of Lantheus from $127.00 to $117.00 and set a "buy" rating for the company in a research note on Thursday. Finally, B. Riley decreased their price objective on shares of Lantheus from $127.00 to $122.00 and set a "buy" rating for the company in a report on Friday, March 21st. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat, Lantheus presently has an average rating of "Moderate Buy" and an average target price of $132.67.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.